Yanadaiah Palakurthi, Kumar Gali Avinash, Babu Molakpogu Ravindra, Vishwas Sukriti, Chaitanya M V N L, Pal Biplab, Kumar Rakesh, Zandi Milad, Gupta Gaurav, MacLoughlin Ronan, Oliver Brian G, Dua Kamal, Singh Sachin Kumar
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Department of Pharmacognosy, Sun Institute of Pharmaceutical Education and Research, Nellore, India.
Rev Med Virol. 2025 Jul;35(4):e70051. doi: 10.1002/rmv.70051.
Monkeypox virus (MPXV) is a zoonotic orthopoxvirus (ORXV) that causes a significant public health concern due to its potential for human-to-human transmission and ability to cause severe disease. Despite the availability of a vaccine, there is currently no specific antiviral treatment for MPXV. The development of effective therapeutic strategies for MPXV is essential to mitigate its harmful impact on society. Various strategies used to treat the MPXV infection include antiviral drugs, immunoglobulins, and supportive care measures. Antiviral drugs, such as cidofovir, brincidofovir, and tecovirimat, have shown promising results in in vitro and animal models, but their efficacy in human MPXV cases is still uncertain. This article provides a comprehensive review of the therapeutic strategies that have been explored for the management of MPXV virus infection. The review further highlights the challenges and limitations associated with the development and implementation of therapeutic strategies for MPXV.
猴痘病毒（MPXV）是一种人畜共患的正痘病毒（ORXV），因其具有人际传播潜力和导致严重疾病的能力而引起了重大的公共卫生关注。尽管有疫苗可用，但目前尚无针对猴痘病毒的特异性抗病毒治疗方法。开发有效的猴痘病毒治疗策略对于减轻其对社会的有害影响至关重要。用于治疗猴痘病毒感染的各种策略包括抗病毒药物、免疫球蛋白和支持性护理措施。抗病毒药物，如西多福韦、布林西多福韦和替考韦玛，在体外和动物模型中已显示出有前景的结果，但其在人类猴痘病例中的疗效仍不确定。本文对已探索的用于管理猴痘病毒感染的治疗策略进行了全面综述。该综述进一步强调了与猴痘病毒治疗策略的开发和实施相关的挑战和局限性。
